| Document |
Document Title |
|
WO/2022/179528A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceut...
|
|
WO/2022/182153A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2022/180080A1 |
The present invention relates to compounds of formula (I) and to salts, solvates, stereoisomers and tautomers thereof useful as anti-proliferative agents and/or as inhibitors of DEAD-box (DDX) RNA helicases. The present invention also pr...
|
|
WO/2022/179529A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formulas (A), (A*), (I), (II), (AA), (B), (C), (D), (B*), (C*) and (D*). Further...
|
|
WO/2022/179636A1 |
The present invention relates to crystal forms I, II, III, IV, V, VI, VII, VIII, and IX of an FXR receptor agonist 2-((1S,4S,5R)-5-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxaz
ol-4-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-yl)benzo[d]thi
...
|
|
WO/2022/182972A1 |
Disclosed herein are substituted aminopyrimidine compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Ar, R1, and R2 have the meanings described herein; pharmaceutical compositions that include such compounds, a...
|
|
WO/2022/180649A1 |
The present invention relates to a novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadia
zol-3-yl)-4,6-dimethylpyridine-1-oxide of formula (I). The present invention also relates to the novel i...
|
|
WO/2022/174796A1 |
Disclosed are a pyrimidine compound represented by formula (1) as a Wee-1 inhibitor, a preparation method therefor, and an application of the compound represented by formula (1) and various isomers, crystal forms, pharmaceutically accept...
|
|
WO/2022/177358A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/177359A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/178283A1 |
Disclosed are compounds and methods for treating tauopathy.
|
|
WO/2022/178269A1 |
Disclosed is the 1:1 phosphate salt of Compound (I) as well as a novel crystal form thereof. Also disclosed is a novel crystal form of Compound (I). The present invention also provides methods of increasing the activity of HMOX-1 in a su...
|
|
WO/2022/175675A1 |
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, U, X, Y and B are as define...
|
|
WO/2022/175889A1 |
The present invention relates to a method for the enantioselective preparation of a compound of formula (I).
|
|
WO/2022/174384A1 |
Disclosed is the 1: 1 phosphate salt of Compound (I) as well as a novel crystal form thereof. Also disclosed is a novel crystal form of Compound (I). The present invention also (compound I) provides methods of increasing the activity of ...
|
|
WO/2022/177405A1 |
The present invention provides a novel compound, and an organic light-emitting device using same.
|
|
WO/2022/175222A1 |
The present invention relates to cryptophycin compounds, to new cryptophycin payloads, to new cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents.
|
|
WO/2022/174803A1 |
The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to...
|
|
WO/2022/171265A1 |
The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I).
|
|
WO/2022/173805A1 |
The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
|
|
WO/2022/174256A1 |
The present disclosure provides compounds, or their tautomers or pharmaceutically acceptable salts thereof, and their pharmaceutical compositions that can selectively activate Yes-associated protein 1 (YAP). YAP activators of the present...
|
|
WO/2022/171472A1 |
The invention relates to isoxazoline compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for...
|
|
WO/2022/171111A1 |
A compound of formula I below as RIP1 kinase inhibitor and uses thereof.
|
|
WO/2022/174268A1 |
The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.
|
|
WO/2022/174193A1 |
The present invention provides a compound which is a class-lla histone deacetylases (HDAC) inhibitor, a process of making the compound, a composition containing the compound and radiolabeling the compound for use in positron emission tom...
|
|
WO/2022/170871A1 |
A novel crystalline modification of Pyroxasulfone is provided, characterized by an X-ray powder diffractogram (XRD), an infrared (IR) spectrum, a melting point and/or a differential scanning calorimetry (DSC) profile. There is also provi...
|
|
WO/2022/171185A1 |
The present invention provides a compound serving as an NLRP3 inhibitor. Specifically, the present invention provides a compound having a structure shown in the following formula (I), or an optical isomer, pharmaceutically acceptable sal...
|
|
WO/2022/170964A1 |
A crystalline hydrate of topramezone sodium salt is provided. A preparation method for the crystalline hydrate of topramezone sodium salt and herbicidal compositions including the crystalline hydrate of topramezone sodium salt are also p...
|
|
WO/2022/167695A1 |
The present invention relates to chromen-4-one derivatives, and to associated multi-salts, solvates, and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and p...
|
|
WO/2022/167697A1 |
The present invention relates to chromen-4-one derivatives, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatm...
|
|
WO/2022/169921A1 |
The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said comp...
|
|
WO/2022/166022A1 |
A purification method for Tedizolid phosphate. A crude product of Tedizolid phosphate is first mixed with absolute ethyl alcohol, impurities having a smaller polarity than the Tedizolid phosphate in the crude product of Tedizolid phospha...
|
|
WO/2022/166721A1 |
The present invention relates to a series of fused ring derivatives containing 1,4-oxazepane and a preparation method therefor, and in particular relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/166917A1 |
A TYK2 inhibitor compound containing a bicyclic ring and the use thereof in the preparation of a drug for treating or preventing TYK2-related diseases.
|
|
WO/2022/167819A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for t...
|
|
WO/2022/166923A1 |
A phenyldihydropyrimidine compound as represented by formula I, a tautomer or a pharmaceutically acceptable salt thereof. The phenyldihydropyrimidine compound has a good anti-HBV activity and can be used for preparing drugs for treating ...
|
|
WO/2022/169897A1 |
Provided herein are crystalline forms of a cyclin-dependent kinases (CDK) inhibitor, compositions thereof, methods of preparation thereof, and methods of use thereof.
|
|
WO/2022/166938A1 |
The present invention relates to the field of herbicides, and in particular, to a uracil compound containing a carboxylate fragment and a preparation method therefor, a herbicidal composition, and a use. The uracil compound containing a ...
|
|
WO/2022/169997A1 |
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/167330A1 |
The present invention relates to a crystalline form of (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(R)-3-(3-[1,2,3]tri
azol-2-yl-benzyl)-morpholin-4-yl]-methanone, a process for the preparation thereof, pharmaceutical compositions comprisin...
|
|
WO/2022/170164A1 |
The invention provides compounds and pharmaceutical compositions thereof, which are useful for inhibiting one or more mutations of EGFR, as well as methods for using such compounds to treat cancer associated with EGFR mutations.
|
|
WO/2022/167699A1 |
The present invention relates to chromen-4-one derivatives, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatm...
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/167698A1 |
The present invention relates to chromen-4-one derivatives, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatm...
|
|
WO/2022/169184A1 |
The present invention relates to a novel compound and an organic light-emitting element comprising the novel compound in one or more organic layers to thus be highly efficient.
|
|
WO/2022/164239A1 |
A novel pyrazole-carboxamide derivative compound provided as one example of the present invention exhibits an antagonist activity specific to cannabinoid receptor 1, and thus has a technical effect of effectively preventing or treating d...
|
|
WO/2022/161274A1 |
Disclosed in the present invention are a pyrimidine-2,4-diamine compound, a preparation method therefor and the use thereof, relating to the technical field of pharmaceutical chemistry. The pyrimidine-2,4-diamine compound of the present ...
|
